{"Background": [0], "Treatment": [1], "of": [2, 36, 78, 107, 185, 210, 314, 362, 369, 384, 394, 415, 425, 434, 439, 447, 452, 461, 472, 495, 506, 520, 533, 549], "locally": [3], "advanced": [4], "rectal": [5, 66, 570], "cancer": [6], "with": [7, 73, 136, 274, 560, 565], "chemoradiotherapy,": [8, 239, 372], "surgery,": [9], "and": [10, 61, 118, 121, 147, 164, 180, 192, 203, 243, 277, 280, 289, 333, 365, 441, 469, 503, 530, 543, 582, 594, 619], "adjuvant": [11, 181, 244, 402, 486, 598], "chemotherapy": [12, 28, 89, 131, 135, 182, 245, 302, 331, 389, 420, 467, 501, 526, 550, 580], "controls": [13], "local": [14], "disease,": [15], "but": [16], "distant": [17, 37], "metastases": [18], "remain": [19], "common.": [20], "We": [21, 40], "aimed": [22], "to": [23, 85, 114, 126, 298], "assess": [24], "whether": [25], "administering": [26], "neoadjuvant": [27, 88, 130, 134, 301, 330, 349, 388, 419, 466, 500, 525, 579], "before": [29, 553], "preoperative": [30, 554, 561], "chemoradiotherapy": [31, 158, 555, 562], "could": [32], "reduce": [33], "the": [34, 87, 108, 257, 300, 306, 329, 337, 351, 373, 387, 398, 404, 418, 428, 465, 476, 481, 499, 510, 524, 537, 578, 583, 588, 601], "risk": [35], "recurrences.": [38], "Methods": [39], "did": [41], "a": [42, 74, 208, 311], "phase": [43], "3,": [44], "open-label,": [45], "multicentre,": [46], "randomised": [47], "trial": [48, 271], "at": [49, 207, 260], "35": [50], "hospitals": [51], "in": [52, 256, 328, 336, 386, 397, 417, 427, 458, 464, 475, 492, 498, 509, 517, 523, 536, 563, 577], "France.": [53], "Eligible": [54], "patients": [55, 294, 396, 474, 508, 522, 535, 564], "were": [56, 81, 123, 265, 295, 323, 358, 411], "adults": [57], "aged": [58], "18\u201375": [59], "years": [60], "had": [62], "newly": [63], "diagnosed,": [64], "biopsy-proven,": [65], "adenocarcinoma": [67], "staged": [68], "cT3": [69, 566], "or": [70, 91, 222, 305, 567], "cT4": [71, 568], "M0,": [72], "WHO": [75], "performance": [76], "status": [77], "0\u20131.": [79], "Patients": [80], "randomly": [82, 296], "assigned": [83, 297], "(1:1)": [84], "either": [86, 299], "group": [90, 132, 237, 303, 308, 332, 339, 390, 421, 468, 478, 502, 512, 527, 539, 581], "standard-of-care": [92, 236, 307, 338, 399, 429, 477, 511, 538], "group,": [93], "using": [94, 551], "an": [95], "independent": [96], "web-based": [97], "system": [98], "by": [99, 103, 197], "minimisation": [100], "method": [101], "stratified": [102], "centre,": [104], "extramural": [105], "extension": [106], "tumour": [109, 116], "into": [110], "perirectal": [111], "fat": [112], "according": [113], "MRI,": [115], "location,": [117], "stage.": [119], "Investigators": [120], "participants": [122, 463, 497], "not": [124], "masked": [125], "treatment": [127, 483], "allocation.": [128], "The": [129, 235, 249, 572], "received": [133, 238], "FOLFIRINOX": [137, 552], "(oxaliplatin": [138], "85": [139, 190], "mg/m2,": [140, 143, 146, 195], "irinotecan": [141], "180": [142], "leucovorin": [144, 193], "400": [145, 194, 199], "fluorouracil": [148, 201], "2400": [149, 211], "mg/m2": [150, 166, 191, 200, 212, 225], "intravenously": [151], "every": [152, 216, 232], "14": [153, 217], "days": [154, 174, 218, 230], "for": [155, 172, 219], "6": [156, 247], "cycles),": [157], "(50": [159], "Gy": [160], "during": [161, 480], "5": [162, 173], "weeks": [163], "800": [165], "concurrent": [167], "oral": [168], "capecitabine": [169, 223], "twice": [170, 227], "daily": [171, 228], "per": [175], "week),": [176], "total": [177, 240], "mesorectal": [178, 241], "excision,": [179, 242], "(3": [183], "months": [184, 316], "modified": [186], "FOLFOX6": [187], "[intravenous": [188], "oxaliplatin": [189], "followed": [196], "intravenous": [198], "bolus": [202], "then": [204], "continuous": [205], "infusion": [206], "dose": [209], "over": [213], "46": [214], "h": [215], "six": [220], "cycles]": [221], "[1250": [224], "orally": [226], "on": [229, 267], "1\u201314": [231], "21": [233], "days]).": [234], "(for": [246], "months).": [248], "primary": [250], "endpoint": [251], "was": [252, 272, 380], "disease-free": [253, 320, 575], "survival": [254, 321, 576], "assessed": [255], "intention-to-treat": [258], "population": [259], "3": [261], "years.": [262], "Safety": [263], "analyses": [264], "done": [266], "treated": [268], "patients.": [269], "This": [270], "registered": [273], "EudraCT": [275], "(2011-004406-25)": [276], "ClinicalTrials.gov": [278], "(NCT01804790)": [279], "is": [281, 591], "now": [282], "complete.": [283], "Findings": [284], "Between": [285], "June": [286, 290], "5,": [287], "2012,": [288], "26,": [291], "2017,": [292], "461": [293], "(n=231)": [304], "(n=230).": [309], "At": [310], "median": [312], "follow-up": [313], "46\u00b75": [315], "(IQR": [317], "35\u00b74\u201361\u00b76),": [318], "3-year": [319], "rates": [322], "76%": [324], "(95%": [325], "CI": [326, 345], "69\u201381)": [327], "69%": [334], "(62\u201374)": [335], "(stratified": [340], "hazard": [341], "ratio": [342], "0\u00b769,": [343], "95%": [344], "0\u00b749\u20130\u00b797;": [346], "p=0\u00b7034).": [347], "During": [348, 371, 401, 485], "chemotherapy,": [350, 403], "most": [352, 374, 405], "common": [353, 375, 406], "grade": [354, 376, 407], "3\u20134": [355, 377, 408], "adverse": [356, 378, 409, 455, 489], "events": [357, 410, 456, 490], "neutropenia": [359, 431], "(38": [360], "[17%]": [361], "225": [363], "patients)": [364], "diarrhoea": [366], "(25": [367], "[11%]": [368, 414], "226).": [370], "event": [379], "lymphopenia": [381, 412], "(59": [382], "[28%]": [383], "212": [385], "vs": [391, 422, 436, 449], "67": [392], "[30%]": [393], "226": [395, 521], "group).": [400], "(18": [413], "161": [416, 435], "42": [423], "[27%]": [424], "155": [426], "group),": [430], "(nine": [432], "[6%]": [433], "28": [437], "[18%]": [438], "155),": [440], "peripheral": [442], "sensory": [443], "neuropathy": [444], "(19": [445], "[12%]": [446], "162": [448], "32": [450], "[21%]": [451], "155).": [453], "Serious": [454], "occurred": [457, 491, 516], "63": [459], "(27%)": [460], "231": [462], "50": [470], "(22%)": [471], "230": [473], "(p=0\u00b7167),": [479], "whole": [482], "period.": [484], "therapy,": [487], "serious": [488], "18": [493], "(11%)": [494], "163": [496], "36": [504], "(23%)": [505], "158": [507], "(p=0\u00b70049).": [513], "Treatment-related": [514], "deaths": [515], "one": [518, 544], "(<1%)": [519], "(sudden": [528], "death)": [529], "two": [531], "(1%)": [532], "227": [534], "(one": [540], "sudden": [541], "death": [542], "myocardial": [545], "infarction).": [546], "Interpretation": [547], "Intensification": [548], "significantly": [556, 573], "improved": [557, 574], "outcomes": [558], "compared": [559], "M0": [569], "cancer.": [571], "decreased": [584], "neurotoxicity": [585], "indicates": [586], "that": [587], "perioperative": [589], "approach": [590], "more": [592], "efficient": [593], "better": [595], "tolerated": [596], "than": [597], "chemotherapy.": [599], "Therefore,": [600], "PRODIGE": [602], "23": [603], "results": [604], "might": [605], "change": [606], "clinical": [607], "practice.": [608], "Funding": [609], "Institut": [610], "National": [611], "du": [612], "Cancer,": [613, 618], "Ligue": [614], "Nationale": [615], "Contre": [616], "le": [617], "R&D": [620], "Unicancer.": [621]}